At a median follow-up of 33.9 months, brentuximab vedotin showed superior outcomes and durable responses vs either methotrexate or bexarotene for patients with previously treated, CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma.
Avapritinib was well tolerated and safe across several dose levels with an ORR of 72% by IWG-MRT-ECNM criteria.
Novel chemotherapy-free combination of avadomide plus obinutuzumab tolerable and active in patients with relapsed/refractory NHL.
The combination of acalabrutinib and obinutuzumab yielded ORR rates exceeding 90% that deepened over time, along with a favorable safety profile.
Mogamulizumab approximately doubled median PFS compared with vorinostat in patients with previously treated CTCL.
In this expert analysis of key data from the Hematology 2017 annual meeting, the clinical implications of new targeted therapeutic strategies in multiple hematologic diseases (NHL, CLL, CTCL, systemic mastocytosis, and acquired TTP) are reviewed by Farrukh Awan, MD, MS; Madeleine Duvic, MD; Daniel J. DeAngelo, MD, PhD; and Marie Ann Scully, MD.
Composite of aTTP-related death, aTTP recurrence, and major thromboembolic events significantly reduced with caplacizumab vs placebo.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.